Ian A.W. Howes

Chief Financial Officer

Ian A.W. Howes servers as Accelerator Life Science Partners’ Chief Financial Officer.  He oversees the firm’s financial, legal, and operations functions.  Mr. Howes has over 20 years of experience in senior financial roles developing early stage life sciences companies. During his career, he has completed numerous rounds of private and public equity and debt transactions, including two initial public offerings. He also has successfully managed multiple M&A transactions for companies where he served as CFO, including the sale of Scioderm to Amicus Therapeutics in 2015 and the sale of Serenex to Pfizer in 2008.

Prior to joining Accelerator, Mr. Howes was CFO of Heart Metabolics, a venture-backed biopharmaceutical company developing drugs for cardiovascular diseases.  Prior to Heart Metabolics, Mr. Howes served as CFO of Scioderm, a venture-backed pediatric orphan disease company that was later acquired by Amicus Therapeutics (NASDAQ: FOLD).  Prior to Scioderm, Mr. Howes served as CFO for Akebia Therapeutics (NASDAQ: AKBA), a biotechnology company developing pharmaceutical drugs for anemia and ophthalmology. At Akebia, Mr. Howes orchestrated four rounds of private equity and debt financing (securing >$50M in financing) and completed a $15M to spin out of Akebia’s non-core assets into Aerpio Therapeutics.

Before Akebia, Mr. Howes served as CFO and Senior VP of Corporate Development of Serenex, an integrated discovery and development-stage oncology company. Prior to Serenex, Mr. Howes served as CFO and VP Operations at Paradigm Genetics (Nasdaq: PDGM). Mr. Howes began his professional career with Coopers & Lybrand in London and is a Chartered Accountant.  He received an M.B.A. from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill and has a B.S. in Accounting and Finance from the University of Warwick.